Management

Carole Ben-Maimon, MD, Chief Executive Officer

Carole Ben-Maimon, MD joined Chondrial Therapeutics in December 2016 as the Chief Executive Officer, bringing more than 25 years experience in the pharmaceutical industry to the company.

 

Most recently, she worked with Deerfield Management Company assisting in the evaluation of investment opportunities in the brand and generic industry. Prior to working with Deerfield, she was President of Global Pharmaceuticals, a subsidiary of Impax Laboratories that was responsible for Impax’s generic business.

 

Dr. Ben-Maimon’s career is further highlighted by leadership roles at several pharmaceutical companies including Barr Pharmaceuticals and Teva Pharmaceutical Industries. At Barr Pharmaceuticals, Dr. Ben-Maimon served as President and COO of the company’s branded female healthcare business and was also a member of the Board of Directors. During her tenure at Teva, Dr. Ben-Maimon was responsible for R&D and public policy in North America. In addition to her executive roles, Dr. Ben-Maimon currently serves on the Board of two emerging, privately-held pharmaceutical companies and serves on the Board of a not-for-profit hospital in Philadelphia.

 

Dr. Ben-Maimon received her B.S. from the University of Pennsylvania and her M.D. from Jefferson Medical College. She completed a residency in internal medicine and a fellowship in nephrology.

R. Mark Payne, MD (CSO) and Co-founder

Dr. Mark Payne, MD, is a co-founder of Chondrial Therapeutics and currently serves as the company’s Chief Scientific Officer. A renowned scientist and practicing physician, Dr. Payne brings to Chondrial a long-standing scientific focus on protein targeting to mitochondria and a dedication to treating cardiomyopathies of childhood, including Friedreich’s Ataxia.

 

In addition to his role at Chondrial, Dr. Payne is a tenured professor of Pediatrics at Indiana University School of Medicine where he directs multiple training, clinical, and research programs. His lab investigates the role of mitochondrial function in heart disease and is funded by multiple sources, including NIH, AHA, and foundation grants. Previously, while at Wake Forrest University, Dr. Payne conducted extensive research of TAT-transduction technology and was the inventor on the patent, Non-viral Delivery of Proteins to Mitochondria. Dr. Payne also works closely with the patient advocacy group, Friedreich’s Ataxia Research Alliance (FARA), as a scientific advisor, and has significant experience in working with large and small pharmaceutical organizations in basic and clinical research.

 

Dr. Payne received his BS degree in Natural Sciences from Washington & Lee University, and his MD from the University of Texas at Houston. He performed his clinical training in pediatrics, his fellowship in pediatric cardiology, and a basic research fellowship in molecular biology at Washington University in St. Louis. He is a Fellow of the American College of Cardiology, and a Fellow of the American Academy of Pediatrics.

John Berman, Vice President of Finance and Operations

John Berman joined Chondrial Therapeutics in January 2017 as the Vice President of Finance and Operations, bringing more than 20 years’ experience to the company.

 

Previously, Mr. Berman spent 14 years at Teva Pharmaceutical Industries where he held various positions of increasing responsibility. Most recently, Mr. Berman held the position of Senior Director of Corporate Alliance Management, where he worked closely for some of the largest brands in the Teva portfolio on both R&D and commercial alliances. Prior to that, he worked on the commercial side of the business where he led the finance team for the branded US Oncology Business, with revenue of nearly $1B. Mr. Berman also served in Teva’s R&D organization where he managed finance and business operations. Prior to joining Teva, John worked in financial planning and analysis at Cell Pathways, CDNow, Toll Brothers, and PricewaterhouseCoopers.

 

Mr. Berman earned a B.A. in Economics from the College of Arts and Sciences at the University of Pennsylvania, and an MBA from the Wharton School at the University of Pennsylvania. Mr. Berman is a Certified Public Accountant and holds the Chartered Financial Analyst designation.

Jennifer Johansson, Vice President of Regulatory Affairs and Counsel

Jennifer Spokes Johansson joined Chondrial Therapeutics in December 2016 as Vice President, Regulatory Affairs and Counsel, bringing more than 20 years of pharmaceutical legal and regulatory experience to the company.

 

Most recently, Ms. Johansson served as senior vice president, regulatory policy and counsel for Putney (acquired by Dechra), an early stage veterinary generics company. While at Putney from company initiation through exit, she was chair of the Generic Animal Drug Alliance and a member of the industry negotiation teams for the Animal Generic Drug User Fee Act and its reauthorization. Prior to Putney, Ms. Johansson served as vice president of regulatory affairs, as well as counsel, for Andrx (now Teva), a human drug company focused on generics and pharmaceutical delivery. Before joining Andrx, she was an associate in a leading food and drug regulatory practice at the law firm of Patton Boggs (now Squire Patton Boggs) in Washington, DC. Ms. Johansson started her career in laboratory research at the National Institutes of Health.

 

Ms. Johansson graduated with an A.B., cum laude with Distinction in Biology from Duke University and holds a J.D., magna cum laude, from Boston University School of Law, where she was an editor of the Boston University Law Review. She is a member of the bars of Massachusetts and Washington, DC.

David Bettoun, Vice President of Pre-Clinical Development

David Bettoun, Ph.D., joined Chondrial Therapeutics in December 2016 as Vice President of Discovery and Preclinical Development, bringing more than 17 years experience to the company.

 

Previously, Dr. Bettoun held leadership roles at myriad pharmaceutical and biotechnology companies where he managed drug discovery programs for various indications and pathways. His most recent position was that of Chief Scientist at HaRo Pharmaceutical, a startup biotech that he co-founded and where he led the discovery and development of novel therapeutics for the treatment of a rare childhood cancer. Prior to that, Dr. Bettoun’s early work at Eli Lilly and Merck focused on discovery research for bone and inflammatory diseases. While at Glaxo SmithKline, Dr. Bettoun successfully managed a challenging lead optimization effort aiming at preventing tissue destruction in patients with COPD.

 

Dr. Bettoun received a bachelor and a master of science in biochemistry from Paul Sabatier University in Toulouse, France. He received his Ph.D. form the department of Physiology at McGill University, in Montréal Canada, and pursued postdoctoral studies in molecular genetics at the Weizmann Institute of Science in Rehovot, Israel.

For more information,

contact us today!